Article Data

  • Views 465
  • Dowloads 151

Original Research

Open Access

Vitexin exerts anti-tumor and anti-angiogensis effects on cervical cancer through VEGFA/VEGFR2 pathway

  • Qianqian Wang1
  • Jinwei Zhang1,*,
  • Jia Ye1,*,
  • Jian Guo1

1Department of Gynecology, Wuxi People’s Hospital, 214023 Wuxi, Jiangsu, China

DOI: 10.22514/ejgo.2022.036 Vol.43,Issue 4,August 2022 pp.86-91

Submitted: 25 March 2022 Accepted: 08 June 2022

Published: 15 August 2022

*Corresponding Author(s): Jinwei Zhang E-mail:
*Corresponding Author(s): Jia Ye E-mail:


Vitexin is widely known as a bioactive flavonoid compound, and exerts analgesic and anti-oxidative properties. Antitumor effect of vitexin was identified in various tumors. Role and related mechanism of vitexin in cervical cancer were investigated. Cervical cancer cells were treated with vitexin, and treatment with vitexin reduced cell viability, and decreased number of colonies in cervical cancer. Moreover, cell migration and invasion were repressed by vitexin, and vitexin inhibited angiogenesis of cervical cancer. Vitexin reduced protein expression of Vascular Endothelial Growth Factor A (VEGFA) and Vascular endothelial growth factor receptor 2 (VEGFR2) of cervical cancer in a dosage dependent way. In conclusion, vitexin reduced cell proliferation, migration, invasion and angiogenesis of cervical cancer through inhibition of VEGFA/VEGFR2 signaling.


Vitexin; Cervical cancer; Proliferation; Migration; Invasion; Angiogenesis; VEGFA/VEGFR2

Cite and Share

Qianqian Wang,Jinwei Zhang,Jia Ye,Jian Guo. Vitexin exerts anti-tumor and anti-angiogensis effects on cervical cancer through VEGFA/VEGFR2 pathway. European Journal of Gynaecological Oncology. 2022. 43(4);86-91.


[1] Jia-qi Duan H-gH, Chun-ling Shui, Wei Jiang, Xi Luo. The cardioprotec-tive effect of dexmedetomidine on elderly patients with cervical cancer in the trendelenburg position. Signa Vitae. 2021; 17: 117–121.

[2] Fu K, Zhang L, Liu R, Shi Q, Li X, Wang M. MiR-125 inhibited cervical cancer progression by regulating VEGF and PI3K/AKT signaling pathway. World Journal of Surgical Oncology. 2020; 18: 115.

[3] Duranti S, Pietragalla A, Daniele G, Nero C, Ciccarone F, Scambia G, et al. Role of immune checkpoint inhibitors in cervical cancer: from preclinical to clinical data. Cancers. 2021; 13: 2089.

[4] Pang Y, Wu S, He Y, Nian Q, Lei J, Yao Y, et al. Plant-derived compounds as promising therapeutics for vitiligo. Frontiers in Pharmacology. 2021; 12: 685116–685116.

[5] Aslam M, Ahmad MS, Mamat A. Pharmacological potential of vitexin. Indian Research Journal of Pharmacy and Science. 2015; 2: 114–122.

[6] He M, Min J, Kong W, He X, Li J, Peng B. A review on the pharmacological effects of vitexin and isovitexin. Fitoterapia. 2016; 115: 74–85.

[7] Ganesan K, Xu B. Molecular targets of vitexin and isovitexin in cancer therapy: a critical review. Annals of the New York Academy of Sciences. 2017; 1401: 102–113.

[8] Zhang G, Li D, Chen H, Zhang J, Jin X. Vitexin induces G2/M-phase arrest and apoptosis via Akt/mTOR signaling pathway in human glioblastoma cells. Molecular Medicine Reports. 2018; 17: 4599–4604.

[9] Lee C, Chien Y, Chiu T, Huang W, Lu C, Chiang J, et al. Apoptosis triggered by vitexin in U937 human leukemia cells via a mitochondrial signaling pathway. Oncology Reports. 2012; 28: 1883–1888.

[10] An F, Wang S, Tian Q, Zhu D. Effects of orientin and vitexin from Trollius chinensis on the growth and apoptosis of esophageal cancer EC-109 cells. Oncology Letters. 2015; 10: 2627–2633.

[11] Zhang L, La X, Tian J, Li H, Li A, Liu Y, et al. The phytochemical vitexin and syringic acid derived from foxtail fillet bran inhibit breast cancer cells proliferation via GRP78/SREBP-1/SCD1 signaling axis. Journal of Functional Foods. 2021; 85: 104620.

[12] Liu N, Wang KS, Qi M, Zhou YJ, Zeng GY, Tao J, et al. Vitexin compound 1, a novel extraction from a Chinese herb, suppresses melanoma cell growth through DNA damage by increasing ROS levels. Journal of Experimental & Clinical Cancer Research. 2018; 37: 269.

[13] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians. 2021; 71: 209–249.

[14] Zhou Y, Liu YE, Cao J, Zeng G, Shen C, Li Y, et al. Vitexins, nature-derived lignan compounds, induce apoptosis and suppress tumor growth. Clinical Cancer Research. 2009; 15: 5161–5169.

[15] Maishi N, Annan DA, Kikuchi H, Hida Y, Hida K. Tumor endothelial heterogeneity in cancer progression. Cancers. 2019; 11: 1511.

[16] Bhat A, Yadav J, Thakur K, Aggarwal N, Tripathi T, Chhokar A, et al. Exosomes from cervical cancer cells facilitate pro-angiogenic endothelial reconditioning through transfer of Hedgehog—GLI signaling components. Cancer Cell International. 2021; 21: 319.

[17] Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005; 69: 4–10.

[18] Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. Journal of the National Cancer Institute. 1995; 87: 1237–1245.

[19] Krill LS, Tewari KS. Exploring the therapeutic rationale for angiogenesis blockade in cervical cancer. Clinical Therapeutics. 2015; 37: 9–19.

[20] Prasad CB, Singh D, Pandey LK, Pradhan S, Singh S, Narayan G. VEGFa/VEGFR2 autocrine and paracrine signaling promotes cervical carcinogenesis via β-catenin and snail. The International Journal of Biochemistry & Cell Biology. 2022; 142: 106122.

[21] Sharma N, Akhtar S, Jamal Q, Kamal M, Khan M, Siddiqui M, et al. Elucidation of antiangiogenic potential of vitexin obtained from cucumis sativus targeting Hsp90 protein: a novel multipathway targeted approach to restrain angiogenic phenomena. Medicinal Chemistry. 2017; 13: 282–291.

[22] Ponte LGS, Pavan ICB, Mancini MCS, da Silva LGS, Morelli AP, Severino MB, et al. The hallmarks of flavonoids in cancer. Molecules. 2021; 26: 2029.

[23] Huang J, Zhou Y, Zhong X, Su F, Xu L. Effects of vitexin, a natural flavonoid glycoside, on the proliferation, invasion, and apoptosis of human U251 glioblastoma cells. Oxidative Medicine and Cellular Longevity. 2022; 2022: 1–13.

[24] Lee M-Y, Shen M-R. Epithelial-mesenchymal transition in cervical carcinoma. American Journal of Translational Research. 2012; 4: 1–13.

[25] Eskander RN, Tewari KS. Targeting angiogenesis in advanced cervical cancer. Therapeutic Advances in Medical Oncology. 2014; 6: 280–292.

[26] Azubuike-Osu SO, Ohanenye IC, Jacob C, Ejike CECC, Udenigwe CC. Beneficial role of vitexin and isovitexin flavonoids in the vascular endothelium and cardiovascular system. Current Nutraceuticals. 2020; 2: 127–134.

[27] Wang J, Zheng X, Zeng G, Zhou Y, Yuan H. Purified vitexin compound 1 inhibits growth and angiogenesis through activation of FOXO3a by inactivation of Akt in hepatocellular carcinoma. International Journal of Molecular Medicine. 2014; 33: 441–448.

[28] Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. Journal of Internal Medicine. 2013; 273: 114–127.

[29] Chen B, Zhang C, Dong P, Guo Y, Mu N. Molecular regulation of cervical cancer growth and invasion by VEGFa. Tumor Biology. 2014; 35: 11587–11593.

[30] Huang Z, Zhao B, Qin Z, Li Y, Wang T, Zhou W, et al. Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis. European Journal of Medicinal Chemistry. 2019; 181: 111541.

[31] Lyu Z, Cao J, Wang J, Lian H. Protective effect of vitexin reduces sevoflurane-induced neuronal apoptosis through HIF-1α, VEGF and p38 MAPK signaling pathway in vitro and in newborn rats. Experimental and Therapeutic Medicine. 2018; 15: 3117–3123.

[32] Zhao S, Guan X, Hou R, Zhang X, Guo F, Zhang Z, et al. Vitexin attenuates epithelial ovarian cancer cell viability and motility in vitro and carcinogenesis in vivo via p38 and ERK1/2 pathways related VEGFA. Annals of Translational Medicine. 2020; 8: 1139–1139.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time